Evidence map›Paper›PMID 21931324›Full record

ArticleLeukemia2012

The bone marrow-expressed antimicrobial cationic peptide LL-37 enhances the responsiveness of hematopoietic stem progenitor cells to an SDF-1 gradient and accelerates their engraftment after transplantation.

W Wu, C H Kim, R Liu, M Kucia, W Marlicz, N Greco, J Ratajczak, M J Laughlin, M Z Ratajczak

Open access · greenAbstract read
In one paragraph

Article in Leukemia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Endogenous Peptide Inhibitors of HIV Entry.Advances in experimental medicine and biology · 2022
    Article
  8. Cathelicidin LL37 Promotes Osteogenic DifferentiationFrontiers in bioengineering and biotechnology · 2021
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Emerging concepts in non-invasive monitoring of Crohn's disease.Therapeutic advances in gastroenterology · 2018
    Review
  17. Mouse Bone Marrow Sca-1Infection and immunity · 2017
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

W WuDepartment of Medicine, Stem Cell Institute at the James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
C H Kim
R Liu
M Kucia
W Marlicz
N Greco
J Ratajczak
M J Laughlin
M Z Ratajczak
Pomeranian Medical University · PLJames Graham Brown Foundation · USCleveland Cord Blood Center · USUniversity of Louisville · USUniversity of Virginia · US

Funding

Novel mechanisms involving complement cascade in stem cell traffickingR01DK074720 · NIDDK · UNIVERSITY OF LOUISVILLE · PI RATAJCZAK, MARIUSZ Z · 2007 to 2020
$4.1M
The CXCR4-SDF-1 Axis in Metastatic RhabdomyosarcomaR01CA106281 · NCI · UNIVERSITY OF LOUISVILLE · PI RATAJCZAK, MARIUSZ Z · 2005 to 2009
$1.3M
NCI NIH HHS NIH R01 CA106281-01NCI NIH HHS R01 CA106281NIDDK NIH HHS NIH R01 DK074720NIDDK NIH HHS R01 DK074720
6 · The paper itself

Abstract

We report that the bone marrow (BM) stroma-released LL-37, a member of the cathelicidin family of antimicrobial peptides, primes/increases the responsiveness of murine and human hematopoietic stem/progenitor cells (HSPCs) to an α-chemokine stromal-derived factor-1 (SDF-1) gradient. Accordingly, LL-37 is upregulated in irradiated BM cells and enhances the chemotactic responsiveness of hematopoietic progenitors from all lineages to a low physiological SDF-1 gradient as well as increasing their (i) adhesiveness, (ii) SDF-1-mediated actin polymerization and (iii) MAPK(p42/44) phosphorylation. Mice transplanted with BM cells ex vivo primed by LL-37 showed accelerated recovery of platelet and neutrophil counts by ∼3-5 days compared with mice transplanted with unprimed control cells. These priming effects were not mediated by LL-37 binding to its receptor and depended instead on the incorporation of the CXCR4 receptor into membrane lipid rafts. We propose that LL-37, which has primarily antimicrobial functions and is harmless to mammalian cells, could be clinically applied to accelerate engraftment as an ex vivo priming agent for transplanted human HSPCs. This novel approach would be particularly important in cord blood transplantations, where the number of HSCs available is usually limited.

Indexed as

Hematopoietic Stem Cell TransplantationAnimalsAntimicrobial Cationic PeptidesCathelicidinsChemokine CXCL12ChemotaxisComplement C5aFemaleHematopoietic Stem CellsMembrane MicrodomainsMiceMice, Inbred C57BLReceptors, Cell SurfaceReceptors, CXCR4Receptors, Formyl PeptideAntimicrobial Cationic PeptidesCathelicidinsChemokine CXCL12Complement C5aCxcl12 protein, mouseCXCR4 protein, mouseformyl peptide receptor 2, mouseReceptors, Cell SurfaceReceptors, CXCR4Receptors, Formyl Peptide

Identifiers

PMID21931324
PMCPMC3244577
OpenAlexW2032814556

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.